High-dose chemotherapy and autologous PBSC infusion for patients with breast cancer

C. Dean Buckner, Lee Schwartzberg, Robert Birch, Charles H. Weaver

Research output: Contribution to journalArticle

Abstract

High-dose chemotherapy with PBSC support can be given in an outpatient setting to patients with breast cancer with low morbidity and mortality. The overwhelming cause of failure is recurrent disease which will require different strategies to overcome. Strategies that are bring evaluated include: more effective induction and consolidation regimens prior to HDC, tandem high-dose therapies and post-HDC immune modulation.

Original languageEnglish (US)
Pages (from-to)149-155
Number of pages7
JournalCancer Research Therapy and Control
Volume7
Issue number1-2
StatePublished - Dec 1 1998

Fingerprint

Outpatients
Breast Neoplasms
Morbidity
Drug Therapy
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

High-dose chemotherapy and autologous PBSC infusion for patients with breast cancer. / Dean Buckner, C.; Schwartzberg, Lee; Birch, Robert; Weaver, Charles H.

In: Cancer Research Therapy and Control, Vol. 7, No. 1-2, 01.12.1998, p. 149-155.

Research output: Contribution to journalArticle

Dean Buckner, C. ; Schwartzberg, Lee ; Birch, Robert ; Weaver, Charles H. / High-dose chemotherapy and autologous PBSC infusion for patients with breast cancer. In: Cancer Research Therapy and Control. 1998 ; Vol. 7, No. 1-2. pp. 149-155.
@article{2c4193a40a794f91865937b993b0b135,
title = "High-dose chemotherapy and autologous PBSC infusion for patients with breast cancer",
abstract = "High-dose chemotherapy with PBSC support can be given in an outpatient setting to patients with breast cancer with low morbidity and mortality. The overwhelming cause of failure is recurrent disease which will require different strategies to overcome. Strategies that are bring evaluated include: more effective induction and consolidation regimens prior to HDC, tandem high-dose therapies and post-HDC immune modulation.",
author = "{Dean Buckner}, C. and Lee Schwartzberg and Robert Birch and Weaver, {Charles H.}",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "7",
pages = "149--155",
journal = "Cancer Research, Therapy and Control",
issn = "1064-0525",
publisher = "Harwood Academic Publishers",
number = "1-2",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous PBSC infusion for patients with breast cancer

AU - Dean Buckner, C.

AU - Schwartzberg, Lee

AU - Birch, Robert

AU - Weaver, Charles H.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - High-dose chemotherapy with PBSC support can be given in an outpatient setting to patients with breast cancer with low morbidity and mortality. The overwhelming cause of failure is recurrent disease which will require different strategies to overcome. Strategies that are bring evaluated include: more effective induction and consolidation regimens prior to HDC, tandem high-dose therapies and post-HDC immune modulation.

AB - High-dose chemotherapy with PBSC support can be given in an outpatient setting to patients with breast cancer with low morbidity and mortality. The overwhelming cause of failure is recurrent disease which will require different strategies to overcome. Strategies that are bring evaluated include: more effective induction and consolidation regimens prior to HDC, tandem high-dose therapies and post-HDC immune modulation.

UR - http://www.scopus.com/inward/record.url?scp=0032440575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032440575&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 149

EP - 155

JO - Cancer Research, Therapy and Control

JF - Cancer Research, Therapy and Control

SN - 1064-0525

IS - 1-2

ER -